# Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

> **NCT05147350** · PHASE1 · TERMINATED · sponsor: **Debiopharm International SA** · enrollment: 38 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** RP-6306 (oral PKMYT1 inhibitor)

## Key facts

- **NCT ID:** NCT05147350
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-09
- **Primary completion:** 2025-02-12
- **Final completion:** 2025-02-12
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Sponsor decided to terminate the study
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05147350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05147350, "Study of RP-6306 With FOLFIRI in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05147350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*